Global Stress Management Market 2022 - Snapshot
The global stress management market is anticipated to increase by USD 5 billion till 2028 at an average annual growth of 3.8 percent as per the latest report by Gen Consulting Company.
This industry report offers market estimates of the global market, followed by a detailed analysis of the product, age group, end user, and region. The global market data on stress management can be segmented by product: medications, devices. The medications segment held the largest revenue share in 2021. Stress management market is further segmented by age group: adults, children, elderly. Among these, the adults segment was accounted for the highest revenue generator in 2021. Based on end user, the stress management market is segmented into: ambulatory surgical centers, hospitals and clinics, others. The hospitals and clinics segment captured the largest share of the market in 2021. On the basis of region, the stress management market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW). According to the research, Europe had the largest share in the global stress management market.
The global stress management market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Abbott Laboratories, Allergan plc, Apple Inc., AstraZeneca plc, Bausch Health Companies Inc., Bristol Myers Squibb (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Lupin Limited, Merck & Co., Mylan N.V., Pfizer Inc., Samsung Electronics Co. Ltd., Takeda Pharmaceutical Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook